RADNOR, PA — Advanced Aesthetic Technologies, Inc. (AAT) has announced that its partner in China, Lanzhou Biotechnique Development Co., Ltd. (LanDev), has secured regulatory approval to market Algeness® VL, a 2.5% agarose gel dermal filler. The product has been approved as a Class III medical device by the National Medical Products Administration, marking it as the first agarose-based injection filler officially authorized for use in China.
Algeness® VL is the result of years of scientific and clinical research aimed at creating a 100% natural and biodegradable injectable filler. Designed to address wrinkles and restore facial volume, this innovative product offers a distinct injection technique and a biocompatible composition that has gained recognition among global aesthetic practitioners.
LanDev, a subsidiary of China National Biotec Group (CNBG) under Sinopharm Group, played a key role in obtaining the registration license for Algeness®, reflecting its expertise in the aesthetic sector. LanDev is notably the sole domestic Chinese manufacturer of botulinum toxin, with its product Hengli holding a significant market share.
Doug Abel, President and CEO of AAT, expressed optimism about this milestone, stating, “We are excited and look forward to the entry of Algeness® into the large aesthetic market in China through our partner LanDev. We believe that LanDev is the ideal partner to maximize the success of Algeness® in China as they are the sole domestic Chinese manufacturer of botulinum toxin… This approval marks a significant accomplishment by the LanDev, CNBG, AAT, and Ghimas teams and our regulatory advisors and partners.”
This approval caps off a series of significant achievements for AAT over the last two years, including advancing its US FDA Pre-Market Authorization clinical trial, obtaining the CE Mark under Medical Device Regulations (MDR), and acquiring a controlling interest in Ghimas, S.p.A., the original developer of Algeness®.
Practitioners globally have praised Algeness® for its unique formulation and clinical results. Dr. Omer Buhsem, a plastic surgeon and Medical Director for Algeness®, emphasized its benefits, noting, “With my patients, I am uniquely able to define the desired shape while working with a product that I have found to be very safe.”
Additionally, dermatologist Dr. Tatjana Pavicic of Munich, Germany, called Algeness® a “true revolution in the field of aesthetic medicine,” highlighting its natural composition, biocompatibility, and patient satisfaction with results.
The approval of Algeness® VL in China signals a pivotal step for Advanced Aesthetic Technologies, further expanding its reach in the growing global market for aesthetic solutions.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.